Spermosens AB (publ)
Spermosens AB (publ) provides diagnostic health care products and services in Sweden. The company offers devices for male infertility for fertility diagnostics and treatments for the IVF market. It develops JUNO-Checked, a device that measures the binding between sperm and egg cell to enable individualized choice of fertility treatment based on measured binding. Spermosens AB (publ) was incorpora… Read more
Spermosens AB (publ) (9R5) - Total Liabilities
Latest total liabilities as of September 2025: €1.06 Million EUR
Based on the latest financial reports, Spermosens AB (publ) (9R5) has total liabilities worth €1.06 Million EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Spermosens AB (publ) - Total Liabilities Trend (2021–2024)
This chart illustrates how Spermosens AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Spermosens AB (publ) Competitors by Total Liabilities
The table below lists competitors of Spermosens AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Silver Sands Resources Corp
PINK:SSRSF
|
USA | $229.05K |
|
Cymbria Corporation
PINK:CYMBF
|
USA | $162.14 Million |
|
Burcon NutraScience Corp
PINK:BRCNF
|
USA | $26.44 Million |
|
RJK Explorations Ltd
PINK:RJKAF
|
USA | $422.19K |
|
Longevity Health Holdings, Inc.
NASDAQ:XAGE
|
USA | $7.28 Million |
|
HAEMONETICS
MU:HAZ
|
Germany | €1.65 Billion |
|
Movinn AS
CO:MOVINN
|
Denmark | Dkr28.94 Million |
|
Iiot-Oxys Inc
PINK:ITOX
|
USA | $3.19 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Spermosens AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Spermosens AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Spermosens AB (publ) (2021–2024)
The table below shows the annual total liabilities of Spermosens AB (publ) from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €3.70 Million | -72.42% |
| 2023-12-31 | €13.41 Million | +249.75% |
| 2022-12-31 | €3.83 Million | +87.90% |
| 2021-12-31 | €2.04 Million | -- |